ArticleInternational journal of emergency medicine2025
Severe hypertension after atropine administration a case report.
Article in International journal of emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atropine, a cholinergic receptor antagonist, counteracts the parasympathetic nervous system's inhibitory effects on the sinus node, thereby increasing heart rate. It is frequently used to manage atrioventricular block, organophosphate and beta-blocker poisoning, and sinus bradycardia. This case report highlights a rare instance of hypertensive urgency induced by atropine administration, emphasizing the clinical significance of this adverse effect. We present a case report involving a 48-year-old male patient scheduled for right inguinal hernia surgery. The patient was administered atropine prior to the procedure and subsequently experienced severe hypertension and a headache, which were treated with labetalol. After 24 h of monitoring, the patient was discharged without further complications. Documenting such cases is crucial for enhancing our understanding of atropine's safety profile and refining management strategies to mitigate associated risks. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.